Elanco Animal Health Incorporated
General ticker "ELAN" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $9.4B (TTM average)
Elanco Animal Health Incorporated follows the US Stock Market performance with the rate: 59.6%.
Estimated limits based on current volatility of 2.8%: low 23.60$, high 24.94$
Factors to consider:
- Total employees count: 9450 (-3.6%) as of 2024
- US accounted for 45.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Acquisition/divestiture risks, Restructuring risks, Supply chain disruptions, Liquidity and credit risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.79$, 28.14$]
- 2026-12-31 to 2027-12-31 estimated range: [15.24$, 26.09$]
Financial Metrics affecting the ELAN estimates:
- Positive: with PPE of 23.6 at the end of fiscal year the price was neutral
- Positive: -5.39 < Operating profit margin, % of 5.34
- Positive: Inventory ratio change, % of 0.75 <= 0.78
- Negative: Operating cash flow per share per price, % of 5.04 <= 6.59
- Positive: -3.75 < Return on assets ratio (scaled to [-100,100]) of -1.71
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: 42.59 < Shareholder equity ratio, % of 49.01 <= 64.29
- Positive: -4.41 < Investing cash flow per share per price, % of -2.51
Short-term ELAN quotes
Long-term ELAN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4,417.00MM | $4,439.00MM | $4,715.00MM |
| Operating Expenses | $4,091.00MM | $4,188.00MM | $4,463.00MM |
| Operating Income | $326.00MM | $251.00MM | $252.00MM |
| Non-Operating Income | $-1,521.00MM | $237.00MM | $-476.00MM |
| Interest Expense | $277.00MM | $339.00MM | $220.00MM |
| R&D Expense | $327.00MM | $344.00MM | $368.00MM |
| Income(Loss) | $-1,195.00MM | $488.00MM | $-224.00MM |
| Taxes | $36.00MM | $150.00MM | $8.00MM |
| Net Income(Loss)* | $-1,231.00MM | $338.00MM | $-232.00MM |
| Stockholders Equity | $6,223.00MM | $6,096.00MM | $6,547.00MM |
| Inventory | $1,735.00MM | $1,574.00MM | $1,737.00MM |
| Assets | $14,362.00MM | $12,614.00MM | $13,358.00MM |
| Operating Cash Flow | $271.00MM | $541.00MM | $560.00MM |
| Capital expenditure | $154.00MM | $147.00MM | $276.00MM |
| Investing Cash Flow | $-169.00MM | $1,158.00MM | $-279.00MM |
| Financing Cash Flow | $-83.00MM | $-1,492.00MM | $-275.00MM |
| Earnings Per Share** | $-2.50 | $0.68 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.